Pamela Kunz, MD
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
- Chief, GI Medical Oncology
- Vice Chief, Diversity, Equity, and Inclusion, Medical Oncology
Education & Training
- Oncology FellowStanford University (2008)
- Chief ResidentStanford University (2005)
- Internal Medicine ResidentStanford University (2004)
- MDDartmouth Medical School (2001)
- BADartmouth College, Biology (1994)
Additional Information
Publications
- Lam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.
- Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-related Cancer 2022, 29: 335-344. PMID: 35324465, PMCID: PMC9257687, DOI: 10.1530/ERC-21-0239.
- Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice 2022, 18: 258-264. PMID: 34652954, DOI: 10.1200/OP.21.00240.
- Sun TY, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, Raj R, Kunz P, Padda SK. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. The European Respiratory Journal 2022, 59 PMID: 34795035, PMCID: PMC8792466, DOI: 10.1183/13993003.01058-2021.
- Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/S1470-2045(21)00572-6.
- Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The Oncologist 2021, 26: 950-955. PMID: 34342086, PMCID: PMC8571741, DOI: 10.1002/onco.13923.
- Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.
- Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021, 50: 890-894. PMID: 34398071, DOI: 10.1097/MPA.0000000000001841.
- Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.
- Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer (Amsterdam, Netherlands) 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.
- Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas 2021, 50: 469-493. PMID: 33939658, DOI: 10.1097/MPA.0000000000001792.
- Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. Journal Of Gastrointestinal Cancer 2021, 52: 212-221. PMID: 32146619, PMCID: PMC7714089, DOI: 10.1007/s12029-020-00375-2.
- Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Journal Of The Endocrine Society 2021, 5: bvaa205. PMID: 33604494, PMCID: PMC7874572, DOI: 10.1210/jendso/bvaa205.
- Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PloS One 2021, 16: e0261994. PMID: 34941969, PMCID: PMC8699912, DOI: 10.1371/journal.pone.0261994.
- Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. The Lancet. Oncology 2020, 21: 1395-1397. PMID: 33152282, DOI: 10.1016/S1470-2045(20)30560-X.
- Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2020, 15: 1577-1598. PMID: 32663527, DOI: 10.1016/j.jtho.2020.06.021.
- Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.
- Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2372-2382. PMID: 32123969, PMCID: PMC7396396, DOI: 10.1007/s00259-020-04709-x.
- Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Scientific Reports 2020, 10: 10943. PMID: 32616904, PMCID: PMC7331689, DOI: 10.1038/s41598-020-68071-6.
- Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 2020, 49: 723-728. PMID: 32433264, PMCID: PMC7253037, DOI: 10.1097/MPA.0000000000001561.
- Riess JW, Jahchan NS, Das M, Zach Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment And Research Communications 2020, 23: 100174. PMID: 32413603, PMCID: PMC7572629, DOI: 10.1016/j.ctarc.2020.100174.
- Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.
- Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2020, 61: 222-227. PMID: 32015164, PMCID: PMC9364765, DOI: 10.2967/jnumed.119.240911.
- Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. The Oncologist 2020, 25: e276-e283. PMID: 32043766, PMCID: PMC7011621, DOI: 10.1634/theoncologist.2019-0466.
- Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2244-2251. PMID: 31350603, DOI: 10.1007/s00259-019-04455-9.
- Pumpalova Y, Kozak MM, von Eyben R, Kunz P, Fisher G, Chang DT, Haraldsdottir S. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal Of Gastrointestinal Oncology 2019, 10: 605-615. PMID: 31392040, PMCID: PMC6657317, DOI: 10.21037/jgo.2019.02.17.
- Waseem N, Aparici CM, Kunz PL. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2019, 60: 882-891. PMID: 30850504, DOI: 10.2967/jnumed.118.217851.
- Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. Organoid Modeling of the Tumor Immune Microenvironment. Cell 2018, 175: 1972-1988.e16. PMID: 30550791, PMCID: PMC6656687, DOI: 10.1016/j.cell.2018.11.021.
- Erdrich J, Schaberg KB, Khodadoust MS, Zhou L, Shelton AA, Visser BC, Ford JM, Alizadeh AA, Quake SR, Kunz PL, Beausang JF. Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies 2018, 4 PMID: 30087100, PMCID: PMC6169824, DOI: 10.1101/mcs.a003004.
- Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas 2018, 47: 958-966. PMID: 30074526, PMCID: PMC6095724, DOI: 10.1097/MPA.0000000000001133.
- Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2578-2584. PMID: 29878866, PMCID: PMC6366953, DOI: 10.1200/JCO.2018.78.5865.
- Mou E, Schapira L, Kunz P. The Power of Trust. JAMA Oncology 2018, 4: 1173-1174. PMID: 29710067, DOI: 10.1001/jamaoncol.2018.0495.
- Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical Therapeutics 2018, 40: 952-962.e2. PMID: 29724499, DOI: 10.1016/j.clinthera.2018.04.006.
- Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.
- Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-related Cancer 2018, 25: 309-322. PMID: 29330194, PMCID: PMC5811631, DOI: 10.1530/ERC-17-0455.
- Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2018, 59: 66-74. PMID: 29025982, PMCID: PMC6910630, DOI: 10.2967/jnumed.117.202275.
- Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clinical Therapeutics 2017, 39: 2158-2168. PMID: 29074312, DOI: 10.1016/j.clinthera.2017.09.013.
- Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. Pancreas 2017, 46: 1381-1385. PMID: 29040196, DOI: 10.1097/MPA.0000000000000932.
- Kunz PL. Understanding Neuroendocrine Tumors-A NET Gain. JAMA Oncology 2017, 3: 1343-1344. PMID: 28448658, DOI: 10.1001/jamaoncol.2017.0575.
- Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017, 46: 707-714. PMID: 28609356, PMCID: PMC5642985, DOI: 10.1097/MPA.0000000000000850.
- Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2017, 8: 457-465. PMID: 28736633, PMCID: PMC5506272, DOI: 10.21037/jgo.2016.12.09.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal Of Medicine 2017, 376: 125-135. PMID: 28076709, PMCID: PMC5895095, DOI: 10.1056/NEJMoa1607427.
- Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 14-23. PMID: 27918724, DOI: 10.1200/JCO.2016.69.2780.
- Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/MPA.0000000000000659.
- Cloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery 2016, 160: 708-13. PMID: 27216830, DOI: 10.1016/j.surg.2016.04.005.
- Margonis GA, Samaha M, Kim Y, Postlewait LM, Kunz P, Maithel S, Tran T, Berger N, Gamblin TC, Mullen MG, Bauer TW, Pawlik TM. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal Of Gastrointestinal Surgery : Official Journal Of The Society For Surgery Of The Alimentary Tract 2016, 20: 1098-105. PMID: 27008594, DOI: 10.1007/s11605-016-3135-x.
- Liu IH, Ford JM, Kunz PL. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews 2016, 44: 1-9. PMID: 26924193, DOI: 10.1016/j.ctrv.2015.11.006.
- Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/oncology Clinics Of North America 2016, 30: 163-77. PMID: 26614375, DOI: 10.1016/j.hoc.2015.09.008.
- Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology 2015, 5: 422. PMID: 28162292, DOI: 10.1016/j.redox.2015.09.035.
- Kunz PL. Carcinoid and neuroendocrine tumors: building on success. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 1855-63. PMID: 25918282, DOI: 10.1200/JCO.2014.60.2532.
- Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. Journal Of Neuro-oncology 2015, 123: 277-82. PMID: 25935109, PMCID: PMC4452613, DOI: 10.1007/s11060-015-1795-0.
- Phan AT, Kunz PL, Reidy-Lagunes DL. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical Advances In Hematology & Oncology : H&O 2015, 13: 1-18; quiz 1 p following 18. PMID: 26430956.
- Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.
- Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 78-108. PMID: 25583772, DOI: 10.6004/jnccn.2015.0011.
- Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International Journal Of Radiation Oncology, Biology, Physics 2014, 90: 918-25. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.
- Paudel N, Kunz PL, Poultsides GA, Koong AC, Chang DT. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical Radiation Oncology 2014, 4: 368-71. PMID: 25407856, DOI: 10.1016/j.prro.2013.11.005.
- Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma.Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. Pancreas 2014, 43: 777-83. PMID: 24632549, DOI: 10.1097/MPA.0000000000000098.
- Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB : The Official Journal Of The International Hepato Pancreato Biliary Association 2014, 16: 304-11. PMID: 23991643, PMCID: PMC3967881, DOI: 10.1111/hpb.12139.
- Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. Journal Of The American College Of Surgeons 2014, 218: 188-95. PMID: 24321190, DOI: 10.1016/j.jamcollsurg.2013.11.001.
- Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Annals Of Surgical Oncology 2013, 20: 1631-8. PMID: 23149854, DOI: 10.1245/s10434-012-2724-5.
- Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013, 42: 557-77. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/MPA.0b013e31828e34a4.
- Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. Journal Of The National Comprehensive Cancer Network : JNCCN 2013, 11: 5-9. PMID: 23307976, DOI: 10.6004/jnccn.2013.0003.
- Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PloS One 2013, 8: e54014. PMID: 23516391, PMCID: PMC3597709, DOI: 10.1371/journal.pone.0054014.
- Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs 2012, 30: 2364-70. PMID: 22331549, PMCID: PMC3703248, DOI: 10.1007/s10637-012-9800-3.
- Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. The American Journal Of Cardiology 2012, 110: 1623-6. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.
- Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 1477-82; quiz 1482. PMID: 23221786, DOI: 10.6004/jnccn.2012.0154.
- Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 3507-15. PMID: 22949151, DOI: 10.1200/JCO.2011.35.8028.
- Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2012, 25: 1128-39. PMID: 22481281, DOI: 10.1038/modpathol.2012.61.
- Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Annals Of Surgical Oncology 2012, 19: 2295-303. PMID: 22396008, DOI: 10.1245/s10434-012-2305-7.
- Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 724-64. PMID: 22679117, DOI: 10.6004/jnccn.2012.0075.
- Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. International Journal Of Radiation Oncology, Biology, Physics 2012, 82: e595-601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.
- Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Applied Immunohistochemistry & Molecular Morphology : AIMM / Official Publication Of The Society For Applied Immunohistochemistry 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/PAI.0b013e31821c821c.
- Kunz PL. A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting 2012, 271-4. PMID: 24451747, DOI: 10.14694/EdBook_AM.2012.32.136.
- Wanta SM, Basina M, Chang SD, Chang DT, Ford JM, Greco R, Kingham K, Merritt RE, Kunz PL. A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors 2011, 3: e45. PMID: 22355500, PMCID: PMC3282450, DOI: 10.4081/rt.2011.e45.
- Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. International Journal Of Radiation Oncology, Biology, Physics 2011, 81: 181-8. PMID: 21549517, DOI: 10.1016/j.ijrobp.2010.05.006.
- Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117: 3342-51. PMID: 21287530, DOI: 10.1002/cncr.25901.
- Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Archives Of Surgery (Chicago, Ill. : 1960) 2011, 146: 724-32. PMID: 21690450, PMCID: PMC3122162, DOI: 10.1001/archsurg.2011.129.
- Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nuclear Medicine Communications 2011, 32: 343-7. PMID: 21412178, DOI: 10.1097/MNM.0b013e328344894b.
- Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-87. PMID: 20665497, DOI: 10.1002/cncr.25481.
- Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-52. PMID: 20564136, DOI: 10.1002/cncr.25246.
- Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. International Journal Of Radiation Oncology, Biology, Physics 2010, 77: 1420-5. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.
- Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical And Experimental Gastroenterology 2010, 3: 79-86. PMID: 21694850, PMCID: PMC3108662, DOI: 10.2147/ceg.s5928.
- Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Journal Of Translational Medicine 2009, 7: 105. PMID: 20003342, PMCID: PMC2796647, DOI: 10.1186/1479-5876-7-105.
- Reiss G, Kunz P, Koin D, Keeffe EB. Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak. Journal Of The American Geriatrics Society 2006, 54: 680-4. PMID: 16686882, DOI: 10.1111/j.1532-5415.2006.00682.x.
- Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2004, 60: 739-56. PMID: 15557950, DOI: 10.1016/s0016-5107(04)02167-4.
- Filiano JJ, Bellimer SG, Kunz PL. Tandem mass spectrometry and newborn screening: pilot data and review. Pediatric Neurology 2002, 26: 201-4. PMID: 11955927, DOI: 10.1016/s0887-8994(01)00384-8.
Departments and Programs
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
- Chief, GI Medical Oncology
- Vice Chief, Diversity, Equity, and Inclusion, Medical Oncology
Education & Training
- Oncology FellowStanford University (2008)
- Chief ResidentStanford University (2005)
- Internal Medicine ResidentStanford University (2004)
- MDDartmouth Medical School (2001)
- BADartmouth College, Biology (1994)
Additional Information
Publications
- Lam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.
- Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-related Cancer 2022, 29: 335-344. PMID: 35324465, PMCID: PMC9257687, DOI: 10.1530/ERC-21-0239.
- Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice 2022, 18: 258-264. PMID: 34652954, DOI: 10.1200/OP.21.00240.
- Sun TY, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, Raj R, Kunz P, Padda SK. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. The European Respiratory Journal 2022, 59 PMID: 34795035, PMCID: PMC8792466, DOI: 10.1183/13993003.01058-2021.
- Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/S1470-2045(21)00572-6.
- Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The Oncologist 2021, 26: 950-955. PMID: 34342086, PMCID: PMC8571741, DOI: 10.1002/onco.13923.
- Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.
- Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021, 50: 890-894. PMID: 34398071, DOI: 10.1097/MPA.0000000000001841.
- Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.
- Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer (Amsterdam, Netherlands) 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.
- Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas 2021, 50: 469-493. PMID: 33939658, DOI: 10.1097/MPA.0000000000001792.
- Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. Journal Of Gastrointestinal Cancer 2021, 52: 212-221. PMID: 32146619, PMCID: PMC7714089, DOI: 10.1007/s12029-020-00375-2.
- Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Journal Of The Endocrine Society 2021, 5: bvaa205. PMID: 33604494, PMCID: PMC7874572, DOI: 10.1210/jendso/bvaa205.
- Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PloS One 2021, 16: e0261994. PMID: 34941969, PMCID: PMC8699912, DOI: 10.1371/journal.pone.0261994.
- Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. The Lancet. Oncology 2020, 21: 1395-1397. PMID: 33152282, DOI: 10.1016/S1470-2045(20)30560-X.
- Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2020, 15: 1577-1598. PMID: 32663527, DOI: 10.1016/j.jtho.2020.06.021.
- Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.
- Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2372-2382. PMID: 32123969, PMCID: PMC7396396, DOI: 10.1007/s00259-020-04709-x.
- Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Scientific Reports 2020, 10: 10943. PMID: 32616904, PMCID: PMC7331689, DOI: 10.1038/s41598-020-68071-6.
- Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 2020, 49: 723-728. PMID: 32433264, PMCID: PMC7253037, DOI: 10.1097/MPA.0000000000001561.
- Riess JW, Jahchan NS, Das M, Zach Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment And Research Communications 2020, 23: 100174. PMID: 32413603, PMCID: PMC7572629, DOI: 10.1016/j.ctarc.2020.100174.
- Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Current Treatment Options In Oncology 2020, 21: 25. PMID: 32172368, DOI: 10.1007/s11864-020-0711-9.
- Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2020, 61: 222-227. PMID: 32015164, PMCID: PMC9364765, DOI: 10.2967/jnumed.119.240911.
- Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. The Oncologist 2020, 25: e276-e283. PMID: 32043766, PMCID: PMC7011621, DOI: 10.1634/theoncologist.2019-0466.
- Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2244-2251. PMID: 31350603, DOI: 10.1007/s00259-019-04455-9.
- Pumpalova Y, Kozak MM, von Eyben R, Kunz P, Fisher G, Chang DT, Haraldsdottir S. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal Of Gastrointestinal Oncology 2019, 10: 605-615. PMID: 31392040, PMCID: PMC6657317, DOI: 10.21037/jgo.2019.02.17.
- Waseem N, Aparici CM, Kunz PL. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2019, 60: 882-891. PMID: 30850504, DOI: 10.2967/jnumed.118.217851.
- Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. Organoid Modeling of the Tumor Immune Microenvironment. Cell 2018, 175: 1972-1988.e16. PMID: 30550791, PMCID: PMC6656687, DOI: 10.1016/j.cell.2018.11.021.
- Erdrich J, Schaberg KB, Khodadoust MS, Zhou L, Shelton AA, Visser BC, Ford JM, Alizadeh AA, Quake SR, Kunz PL, Beausang JF. Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor Molecular Case Studies 2018, 4 PMID: 30087100, PMCID: PMC6169824, DOI: 10.1101/mcs.a003004.
- Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas 2018, 47: 958-966. PMID: 30074526, PMCID: PMC6095724, DOI: 10.1097/MPA.0000000000001133.
- Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2578-2584. PMID: 29878866, PMCID: PMC6366953, DOI: 10.1200/JCO.2018.78.5865.
- Mou E, Schapira L, Kunz P. The Power of Trust. JAMA Oncology 2018, 4: 1173-1174. PMID: 29710067, DOI: 10.1001/jamaoncol.2018.0495.
- Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical Therapeutics 2018, 40: 952-962.e2. PMID: 29724499, DOI: 10.1016/j.clinthera.2018.04.006.
- Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.
- Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-related Cancer 2018, 25: 309-322. PMID: 29330194, PMCID: PMC5811631, DOI: 10.1530/ERC-17-0455.
- Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2018, 59: 66-74. PMID: 29025982, PMCID: PMC6910630, DOI: 10.2967/jnumed.117.202275.
- Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clinical Therapeutics 2017, 39: 2158-2168. PMID: 29074312, DOI: 10.1016/j.clinthera.2017.09.013.
- Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. Pancreas 2017, 46: 1381-1385. PMID: 29040196, DOI: 10.1097/MPA.0000000000000932.
- Kunz PL. Understanding Neuroendocrine Tumors-A NET Gain. JAMA Oncology 2017, 3: 1343-1344. PMID: 28448658, DOI: 10.1001/jamaoncol.2017.0575.
- Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017, 46: 707-714. PMID: 28609356, PMCID: PMC5642985, DOI: 10.1097/MPA.0000000000000850.
- Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2017, 8: 457-465. PMID: 28736633, PMCID: PMC5506272, DOI: 10.21037/jgo.2016.12.09.
- Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal Of Medicine 2017, 376: 125-135. PMID: 28076709, PMCID: PMC5895095, DOI: 10.1056/NEJMoa1607427.
- Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 14-23. PMID: 27918724, DOI: 10.1200/JCO.2016.69.2780.
- Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/MPA.0000000000000659.
- Cloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery 2016, 160: 708-13. PMID: 27216830, DOI: 10.1016/j.surg.2016.04.005.
- Margonis GA, Samaha M, Kim Y, Postlewait LM, Kunz P, Maithel S, Tran T, Berger N, Gamblin TC, Mullen MG, Bauer TW, Pawlik TM. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal Of Gastrointestinal Surgery : Official Journal Of The Society For Surgery Of The Alimentary Tract 2016, 20: 1098-105. PMID: 27008594, DOI: 10.1007/s11605-016-3135-x.
- Liu IH, Ford JM, Kunz PL. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews 2016, 44: 1-9. PMID: 26924193, DOI: 10.1016/j.ctrv.2015.11.006.
- Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/oncology Clinics Of North America 2016, 30: 163-77. PMID: 26614375, DOI: 10.1016/j.hoc.2015.09.008.
- Scicinski J, Fisher G, Carter C, Cho-Phan C, Kunz P, Ning S, Knox S, Oronsky B, Caroen S, Parker C, Fanger G, Reid T. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology 2015, 5: 422. PMID: 28162292, DOI: 10.1016/j.redox.2015.09.035.
- Kunz PL. Carcinoid and neuroendocrine tumors: building on success. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 1855-63. PMID: 25918282, DOI: 10.1200/JCO.2014.60.2532.
- Nagpal S, Recht CK, Bertrand S, Thomas RP, Ajlan A, Pena J, Gershon M, Coffey G, Kunz PL, Li G, Recht LD. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. Journal Of Neuro-oncology 2015, 123: 277-82. PMID: 25935109, PMCID: PMC4452613, DOI: 10.1007/s11060-015-1795-0.
- Phan AT, Kunz PL, Reidy-Lagunes DL. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Clinical Advances In Hematology & Oncology : H&O 2015, 13: 1-18; quiz 1 p following 18. PMID: 26430956.
- Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.
- Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. Journal Of The National Comprehensive Cancer Network : JNCCN 2015, 13: 78-108. PMID: 25583772, DOI: 10.6004/jnccn.2015.0011.
- Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, Poultsides GA, Visser BC, Norton JA, Kamaya A, Cox VL, Columbo LA, Koong AC, Chang DT. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. International Journal Of Radiation Oncology, Biology, Physics 2014, 90: 918-25. PMID: 25585785, DOI: 10.1016/j.ijrobp.2014.06.066.
- Paudel N, Kunz PL, Poultsides GA, Koong AC, Chang DT. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical Radiation Oncology 2014, 4: 368-71. PMID: 25407856, DOI: 10.1016/j.prro.2013.11.005.
- Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma.Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. Pancreas 2014, 43: 777-83. PMID: 24632549, DOI: 10.1097/MPA.0000000000000098.
- Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB : The Official Journal Of The International Hepato Pancreato Biliary Association 2014, 16: 304-11. PMID: 23991643, PMCID: PMC3967881, DOI: 10.1111/hpb.12139.
- Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. Journal Of The American College Of Surgeons 2014, 218: 188-95. PMID: 24321190, DOI: 10.1016/j.jamcollsurg.2013.11.001.
- Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Annals Of Surgical Oncology 2013, 20: 1631-8. PMID: 23149854, DOI: 10.1245/s10434-012-2724-5.
- Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013, 42: 557-77. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/MPA.0b013e31828e34a4.
- Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. Journal Of The National Comprehensive Cancer Network : JNCCN 2013, 11: 5-9. PMID: 23307976, DOI: 10.6004/jnccn.2013.0003.
- Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PloS One 2013, 8: e54014. PMID: 23516391, PMCID: PMC3597709, DOI: 10.1371/journal.pone.0054014.
- Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs 2012, 30: 2364-70. PMID: 22331549, PMCID: PMC3703248, DOI: 10.1007/s10637-012-9800-3.
- Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. The American Journal Of Cardiology 2012, 110: 1623-6. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.
- Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 1477-82; quiz 1482. PMID: 23221786, DOI: 10.6004/jnccn.2012.0154.
- Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: 3507-15. PMID: 22949151, DOI: 10.1200/JCO.2011.35.8028.
- Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2012, 25: 1128-39. PMID: 22481281, DOI: 10.1038/modpathol.2012.61.
- Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Annals Of Surgical Oncology 2012, 19: 2295-303. PMID: 22396008, DOI: 10.1245/s10434-012-2305-7.
- Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network : JNCCN 2012, 10: 724-64. PMID: 22679117, DOI: 10.6004/jnccn.2012.0075.
- Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. International Journal Of Radiation Oncology, Biology, Physics 2012, 82: e595-601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.
- Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Applied Immunohistochemistry & Molecular Morphology : AIMM / Official Publication Of The Society For Applied Immunohistochemistry 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/PAI.0b013e31821c821c.
- Kunz PL. A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society Of Clinical Oncology Educational Book / ASCO. American Society Of Clinical Oncology. Meeting 2012, 271-4. PMID: 24451747, DOI: 10.14694/EdBook_AM.2012.32.136.
- Wanta SM, Basina M, Chang SD, Chang DT, Ford JM, Greco R, Kingham K, Merritt RE, Kunz PL. A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors 2011, 3: e45. PMID: 22355500, PMCID: PMC3282450, DOI: 10.4081/rt.2011.e45.
- Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. International Journal Of Radiation Oncology, Biology, Physics 2011, 81: 181-8. PMID: 21549517, DOI: 10.1016/j.ijrobp.2010.05.006.
- Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117: 3342-51. PMID: 21287530, DOI: 10.1002/cncr.25901.
- Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Archives Of Surgery (Chicago, Ill. : 1960) 2011, 146: 724-32. PMID: 21690450, PMCID: PMC3122162, DOI: 10.1001/archsurg.2011.129.
- Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, Quon A. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nuclear Medicine Communications 2011, 32: 343-7. PMID: 21412178, DOI: 10.1097/MNM.0b013e328344894b.
- Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-87. PMID: 20665497, DOI: 10.1002/cncr.25481.
- Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-52. PMID: 20564136, DOI: 10.1002/cncr.25246.
- Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. International Journal Of Radiation Oncology, Biology, Physics 2010, 77: 1420-5. PMID: 20056345, DOI: 10.1016/j.ijrobp.2009.06.049.
- Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical And Experimental Gastroenterology 2010, 3: 79-86. PMID: 21694850, PMCID: PMC3108662, DOI: 10.2147/ceg.s5928.
- Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Journal Of Translational Medicine 2009, 7: 105. PMID: 20003342, PMCID: PMC2796647, DOI: 10.1186/1479-5876-7-105.
- Reiss G, Kunz P, Koin D, Keeffe EB. Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak. Journal Of The American Geriatrics Society 2006, 54: 680-4. PMID: 16686882, DOI: 10.1111/j.1532-5415.2006.00682.x.
- Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy 2004, 60: 739-56. PMID: 15557950, DOI: 10.1016/s0016-5107(04)02167-4.
- Filiano JJ, Bellimer SG, Kunz PL. Tandem mass spectrometry and newborn screening: pilot data and review. Pediatric Neurology 2002, 26: 201-4. PMID: 11955927, DOI: 10.1016/s0887-8994(01)00384-8.
Departments and Programs